Relmada Therapeutics, Inc.

NasdaqGS:RLMD Stock Report

Market Cap: US$20.2m

Relmada Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:RLMD Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
20 May 25BuyUS$174,713Sergio TraversaIndividual350,000US$0.56
20 May 25BuyUS$97,208Maged ShenoudaIndividual200,000US$0.52
16 May 25BuyUS$103,330Charles EnceIndividual228,961US$0.45
16 May 25BuyUS$86,060Paul KellyIndividual200,000US$0.43
11 Sep 24BuyUS$149,701Maged ShenoudaIndividual53,432US$2.95
11 Sep 24BuyUS$395,115Sergio TraversaIndividual140,000US$2.99
09 Sep 24BuyUS$64,750Paul KellyIndividual25,000US$2.59
09 Sep 24BuyUS$33,280Charles CasamentoIndividual13,000US$2.56

Insider Trading Volume

Insider Buying: RLMD insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of RLMD?
Owner TypeNumber of SharesOwnership Percentage
Hedge Funds2,050,0006.18%
Private Companies3,017,4209.09%
Individual Insiders3,602,51510.9%
Institutions6,282,14418.9%
General Public18,239,54355%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 43.58% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
9.09%
Trigone Pharma Ltd.
3,017,420US$1.8m0%no data
6.18%
Squadron Capital Management Llc
2,050,000US$1.3m0%no data
5.72%
Kevin Kotler
1,899,930US$1.2m0%no data
3.7%
Acadian Asset Management LLC
1,227,928US$749.0k0%no data
3.64%
The Vanguard Group, Inc.
1,208,075US$736.9k-3.87%no data
2.21%
Sergio Traversa
734,024US$447.8k91.1%no data
1.71%
BlackRock, Inc.
566,905US$345.8k-4.45%no data
1.49%
Palo Alto Investors LP
495,146US$302.0k0%0.06%
1.24%
Paul Kelly
412,295US$251.5k94.2%no data
0.91%
Geode Capital Management, LLC
301,883US$184.1k-0.32%no data
0.87%
Maged Shenouda
288,335US$175.9k226%no data
0.87%
Two Sigma Advisers, LP
288,000US$175.7k44.8%no data
0.83%
AdvisorShares Investments, LLC
276,514US$168.7k31.6%0.02%
0.81%
Charles Ence
267,931US$163.4k588%no data
0.68%
Deutsche Asset & Wealth Management
224,846US$137.2k0%no data
0.51%
Two Sigma Investments, LP
170,544US$104.0k33.7%no data
0.49%
Parsons Capital Management, Inc.
163,336US$99.6k0%0.01%
0.49%
RBF Capital LLC
163,261US$99.6k0%0.01%
0.44%
UBS Asset Management AG
144,789US$88.3k-32.7%no data
0.37%
Renaissance Technologies LLC
124,100US$75.7k-24.6%no data
0.36%
Goldman Sachs Asset Management, L.P.
120,852US$73.7k0%no data
0.32%
State Street Global Advisors, Inc.
106,735US$65.1k0%no data
0.3%
MGO One Seven LLC
100,000US$61.0k0%no data
0.18%
Northern Trust Global Investments
59,571US$36.3k-29.3%no data
0.16%
Hudson River Trading LLC, Asset Management Arm
52,043US$31.7k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/30 08:31
End of Day Share Price 2025/06/27 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Relmada Therapeutics, Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maxim JacobsEdison Investment Research
Lin TsaiJefferies LLC
Marc GoodmanLeerink Partners LLC